title: Doxycycline-loaded β-tricalcium phosphate release following EDTA root surface etching improved the clinical outcomes in chronic periodontitis: an in vivo study.
abstract: BACKGROUND
  The main objective of the present study is to quantify doxycycline (DOX) release from β-tricalcium phosphate (β-TCP) after EDTA root surface treatment.
  
  
  METHODS
  Thirty systemically healthy patients with ≥1 paired contralateral interproximal intrabony defect ≥4 mm deep along with an interproximal probing depth ≥6 mm and clinical attachment level ≥4 mm were randomized into two groups. Group 1 (G1) consisted of sites treated with open flap debridement followed by placement of DOX blended with β-TCP (DOX-β-TCP), whereas group 2 (G2) sites were treated with flap surgery followed by the placement of DOX blended with β-TCP after EDTA etching of the exposed root surfaces (DOX-β-TCP + EDTA). Samples of gingival crevicular fluid (GCF) were obtained 1, 3, 7, 14, and 21 days after surgery. Quantitative measurements of DOX were taken with high-performance liquid chromatography. Clinical evaluation and follow-up for 6 months were performed.
  
  
  RESULTS
  At 21 days, the DOX-β-TCP + EDTA-treated group showed a 194.7 µg/mL value. The DOX-β-TCP + EDTA-treated group retained more DOX during the periods of 3, 7, 10, 14, and 21 days than the DOX-β-TCP-treated group. Six months after therapy, DOX-β-TCP + EDTA-treated sites showed more significant clinical improvements compared to DOX-β-TCP-treated sites (P ≤ 0.05).
  
  
  CONCLUSIONS
  EDTA root surface etching enhances DOX availability in the GCF following its release from β-TCP as a drug carrier.
authors.affiliation: Faculty of Dental Medicine, Department of Periodontology, Al-Azhar University, Cairo, Egypt.
authors.forename: Ahmed Y
authors.initials: AY
authors.lastname: Gamal
authors.forename: Radi M
authors.initials: RM
authors.lastname: Kumper
authors.forename: Abd El Reheem R
authors.initials: Ael R
authors.lastname: Al Gendy
mesh_terms: D000134:Acid Etching, Dental / Q000379:methods*; D000328:Adult; D016301:Alveolar Bone Loss / Q000601:surgery; D001672:Biocompatible Materials / Q000737:chemistry*; D002130:Calcium Phosphates / Q000737:chemistry*; D002851:Chromatography, High Pressure Liquid; D055113:Chronic Periodontitis / Q000601:surgery*; D003646:Debridement; D004318:Doxycycline / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D004337:Drug Carriers; D004492:Edetic Acid / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005883:Gingival Crevicular Fluid / Q000737:chemistry; D006801:Humans; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics*; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000601:surgery; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000601:surgery; D016037:Single-Blind Method; D013524:Surgical Flaps / Q000601:surgery; D014092:Tooth Root / Q000187:drug effects*; D016896:Treatment Outcome
chemical_list: D001672:Biocompatible Materials; D002130:Calcium Phosphates; D004337:Drug Carriers; D061965:Matrix Metalloproteinase Inhibitors; C485817:beta-tricalcium phosphate; D004492:Edetic Acid; D004318:Doxycycline